Sun Pharma Announces Positive Two-Year LEQSELVI Data in Severe Alopecia Areata
Sun Pharmaceutical Industries Ltd · Press Release · 01 Oct 2026, 11:16 pm
Sun Pharma Announces Positive Two-Year LEQSELVI Data in Severe Alopecia Areata Sun Pharma presented two-year open-label extension data for LEQSELVI (deuruxolitinib 8 mg BID) at the EADV Congress on 1st Oct'26, showing sustained efficacy and consistent safety in severe alopecia areata. Among baseline responders, 93.9% maintained response (SALT score ≤20) through Week 108. Of initial nonresponders achieving response at Week 52, 96.8% maintained efficacy through Week 108. Safety remained consistent with earlier trials, showing mostly mild-to-moderate adverse events and no deaths, thrombosis, or major adverse cardiovascular events at the FDA-approved dosage.
Original exchange filing (PDF)
More announcements from Sun Pharmaceutical Industries Ltd
- Intimation of Schedule of Analyst/Institutional Investor Meeting · 05 Nov 2026
- Q2FY27 Earnings Call Transcript · 05 Nov 2026
- Clarification regarding news report relating to the Company''s Assam facility · 03 Nov 2026
- The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on November 2, 2026, with reference to news appeared in https://www.thehindu.com/ dated October 30, 2026 quoting .... · 02 Nov 2026
- Completion and results of postal ballot dated 01 October 2026 · 01 Nov 2026
- Q2FY27- Investor Call Audio Recording · 31 Oct 2026
- Board Meeting Outcome - Conclusion · 30 Oct 2026
- Unaudited Financial Results for the quarter and half year ended 30 September 2026 · 30 Oct 2026
